• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$44.28 $0.04 (0.09%)

REAL-TIME: Last trade at

GlaxoSmithKline

NYSE:GSK

Senate passes FDA funding bill, Reuters reports

Immune Response BioPharma Terminates Blockbuster MS Drug NeuroVax Partnership Discussions With GlaxoSmithKline

Innovative public-private collaboration launches to tackle antibiotic research

GlaxoSmithKline and AstraZeneca invest in antibiotic research

Drug Giants Such as AstraZeneca PLC, GlaxoSmithKline, Sanofi (France) Join Forces With Academia on $285 Million Antibiotic Pact

GlaxoSmithKline Sifts Through Collaborations for Acquisitions

GlaxoSmithKline's next target: Companies it collaborates with, Bloomberg reports

GSK won't swallow poison pill to buy Human Genome

GSK amends HGS offer after poison pill

Human Genome downgraded to Market Perform from Outperform at BMO CapitalGlaxoSmithKline

Keeping an Eye on the Eurozone

Pharma's Rare Disease Strategy

GlaxoSmithKline Amends Offer In Response To Human Genome Poison Pill

GSK addresses Human Genome poison pill

Iroko Pharmaceuticals Engages SynopiaRx to Navigate Managed Care Landscape

Iroko Pharmaceuticals Engages SynopiaRx to Navigate Managed Care Landscape

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

GlaxoSmithKline: The Good News Just Keeps On Coming

Company news: Auxilium and GSK; J&J's Janssen

Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK

Auxilium, GSK enter sales deal for testosterone gel

Human Genome Sciences Rejects GlaxoSmithKline's $2.6 Billion Offer

A 'Least-Bad' Option For Foreign Developed Equity Exposure

Sanofi: Kiss This Stock Goodbye

Investment Choices For Melanoma Awareness Month

Auxilium, GlaxoSmithKline enter co-promotion agreement for Testim

Birmingham bids for clinical drug trials

AstraZeneca looks to revive experimental drugs

Two overall winners announced at prestigious national award ceremony in London’s Science Museum

GlaxoSmithKline completes transaction to increase its ownership in Theravance

GSK statement on tender offer to acquire Human Genome Sciences

GlaxoSmithKline's Melanoma Cocktail Slows Cancer in Study

Glaxo Undeterred by Human Genome 'Poison Pill'

GlaxoSmithKline has upside following melanoma data, says Citigroup

GlaxoSmithKline presents safety, efficacy results for dabrafenib

Glaxo undeterred by Human Genome 'poison pill'

HGS adopts poison pill to thwart GSK, in talks with other firms

Human Genome adopts poison pill to thwart $2.6-bn hostile GSK bid

GlaxoSmithKline target adopts ‘poison pill’

See More Articles...